Maaisha has been covering politics and policy shaping the pharmaceutical industry for several years. Prior to joining Pink Sheet, she covered Food and Drug Administration, National Institutes of Health, vaccines and drug pricing at Inside Health Policy. Her path into the field began with internships at STAT and later at Transmitter. She was the Online News Association Student Newsroom and Innovation Fellow for 2021 and SABEW Health Care Symposium Fellow for 2026. Maaisha also enjoys writing about cinema.
Health and Human Services Secretary Robert F. Kennedy Jr. said criticism of FDA Commissioner Martin Makary stems from industry anger over tougher evidentiary standards.
The FDA’s Pharmacy Compounding Advisory Committee review of peptides is an early policy step, but rulemaking and manufacturing constraints may delay its impact.
Acting CDER Director Tracy Beth Høeg said the FDA could develop guidance so other firms could use the approach taken to add cerebral folate deficiency to the leucovorin label.